The number of diagnosed incident cases of head and neck squamous cell carcinoma (HNSCC) are projected to climb from 229,000 cases in 2024 to 273,000 cases in 2034 across the eight major markets (8MM: the US, France, Germany, Italy, Spain, the UK, Japan, and China), according to GlobalData’s ‘Head and Neck Squamous Cell Carcinoma: Eight-Market Drug Forecast and Market Analysis 2024–34‘ (GDHCHT669) report. Key drivers of this growth include tobacco use, areca nut chewing, alcohol consumption, and human papillomavirus.
Major unmet needs persist in HNSCC. Standard-of-care regimens with curative intent typically demand intensive surgery, prolonged radiation, and full-dose platinum-based chemotherapy, all of which are treatments that many patients cannot tolerate. This is particularly true for frail and elderly patients, who represent nearly 40% of HNSCC cases today and are projected to grow to 44% of HNSCC cases by 2034. Even in early-stage disease, where cure rates reach 70%–90%, a meaningful subset of patients still relapse, often locoregionally, requiring multimodal management. Aggressive treatment can compromise quality of life and cause permanent loss of speech, hearing, or swallowing function. Locoregional progression is frequently the main driver of morbidity and mortality in HNSCC, making locoregional control a critical and distinct therapeutic goal.
Three agents are emerging for these underserved populations, each aiming to improve locoregional control while limiting the systemic toxicity that makes standard regimens intolerable for many patients. Johnson & Johnson’s JNJ-1900 (formerly NBTXR3) is a potentially first-in-class radioenhancer composed of functionalised hafnium oxide nanoparticles, delivered by a single intratumoral injection and activated by radiotherapy. The pivotal NANORAY-312 Phase III trial targets platinum-ineligible patients aged 65 years or older with locally advanced HNSCC receiving definitive radiotherapy with or without cetuximab. The FDA granted JNJ-1900 a fast track designation in 2020, and the programme spans multiple other solid tumours. Key opinion leaders (KOLs) interviewed by GlobalData emphasised the rationale behind this, stating: “Our primary goal is to enhance the effectiveness of radiotherapy in the locally advanced setting…We must continue to explore these specific compounds, as they appear to enhance the potential for curing locally advanced tumours.”
Rakuten Medical’s Akalux (cetuximab sarotalocan) is an epidermal growth factor receptor-targeted photoimmunotherapy agent that was approved in the Japan Conditional Early Approval System in 2020 for unresectable locally advanced or locally recurrent HNSCC. This drug-device combination uses a light-activated antibody-dye conjugate in combination with laser beam irradiation. Treatment spans one to four sessions.
Akalux is reported to have a limited effect on surrounding normal tissues, thereby preserving organ functions. Two global Phase III trials are now underway in patients with locally recurrent HNSCC without distant metastasis in combination with MSD’s Keytruda (pembrolizumab) in the first-line setting and as a monotherapy in later lines.
Steboronine (borofalan¹⁰B) is a boron neutron capture therapy (BNCT) developed by Stella Pharma Corporation. It was approved in Japan in 2020 based on a Japanese, open‐label, uncontrolled trial (Study 002) and indicated for unresectable locally advanced or recurrent HNSCC. A single intravenous dose of Steboronine is followed by neutron beam irradiation.
The clinical development landscape for frail HNSCC patients remains nascent, but the substantial unmet need presents a significant opportunity. Agents that broaden the treatable population without the toxicity burden of standard regimens are well-positioned to capture meaningful market share. The question is no longer whether this population will be treated differently; it is which agents will define the new standards in which markets. While head-to-head data is not yet available, NBTXR3 appears to be the best-positioned drug out of the three for a broad global impact as it requires no specialist laser or neutron accelerator, relying instead on existing radiotherapy infrastructure. GlobalData forecasts that NBTXR3 will reach sales of $108m in HNSCC across the 8MM by 2034. Akalux is a genuinely innovative modality, and Rakuten Medical is clearly committed, as a $100m Series F closed in January 2026, oversubscribed and doubled its initial target to support the global Phase III trial. GlobalData forecasts that it will reach sales of $77.6m in HNSCC across the 8MM by 2034. Steboronine’s global reach will remain constrained by neutron accelerator infrastructure for the foreseeable future, with GlobalData forecasting Japan-only sales of less than $1m by 2034.
